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ABSTRACT
Objectives: Gray matter (GM) atrophy is common in multiple sclerosis (MS), as is cognitive dys-
function. Understanding the exact relationship between atrophy and cognition requires further
investigation. The aim of this study was to investigate the relationship between subcortical GM
atrophy and cognition in early relapsing onset MS.
Methods:Structural MRI and neuropsychological evaluations were performed in 120 patients (80
women) and 50 controls (30 women), part of an early inception cohort, 6 years postdiagnosis.
Deep GM volumes were segmented automatically. Cognition was assessed in 7 domains. Step-
wise linear regression was used to predict average cognition in the patient group.
Results: Most deep GM volumes were reduced in patients, with larger effects on average in men
(11%) than in women (6.3%). Only the bilateral hippocampus, amygdala, and right nucleus
accumbens in men, and right hippocampus and nucleus accumbens, bilateral amygdala, and puta-
men in women, showed no atrophy compared to controls. All cognitive domains except visuospa-
tial memory were affected in men; none were significantly affected in women. In the MS group,
average cognition was best predicted by thalamic volume, sex, and education (adjusted R2 
0.31), while lesion volume was not a significant predictor in the model.
Conclusions: Six years postdiagnosis, almost all subcortical structures were affected by MS,
especially in men. Cognition was most severely affected in male patients. Thalamic volume, sex,
and education best predicted average cognition. These results underline the relevance of
specific subcortical structures to cognition, as well as the relevance of (sex-specific) atrophy
in MS. Neurology® 2012;79:1754–1761
GLOSSARY
BRB-N  Brief Repeatable Battery for Neurological disease; DGM  deep gray matter; DMT  disease-modifying therapy;
EDSS  Expanded Disability Status Scale; GLM  general linear model; GM  gray matter; MS multiple sclerosis; NBV 
normalized whole brain volume; NCGMV  normalized cortical gray matter volume; NDGMV  normalized deep gray matter
volume; NGMV  normalized total gray matter volume; NWMV  normalized total white matter volume; RRMS  relapsing-
remitting multiple sclerosis; WMwhite matter.
Atrophy of the gray matter (GM) and white matter (WM) is frequently found in multiple
sclerosis (MS),1,2 and can be reliably measured with MRI.3 Although already present in early
stages, GM atrophy becomes much more dominant in the progressive phase of the disease.4 As
the clinical relevance and the specific histopathologic substrate of GM atrophy in MS is not
well known, it is the subject of many recent studies.5,6
While the relationship between brain atrophy and clinical measures has been investigated
extensively in the past,7 how atrophy relates to cognition is only recently becoming clearer.8–11
As cognitive dysfunction is common and present in all stages of the disease,12–15 exploring the
relationship between atrophy and cognition could provide valuable new information.
As most studies that focus on the relationship between atrophy and cognition have applied
methods of whole-brain or central atrophy that lack regional specificity, the effect of localized
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atrophy on cognition is at present insuffi-
ciently clear. Recent methodologic advances
have led to reliable volume estimation of (sub)
cortical structures.16–18 Apart from an effect
on information processing speed,19 the effect
of deep gray matter (DGM) atrophy on other
cognitive domains remains unclear. In addition,
while cognitive dysfunction differs between
sexes,13,20 whether potential sex differences in
MS-inflicted DGM atrophy affect cognition has
not been studied before.
The aim of this study was therefore to inves-
tigate the possibly sex-specific relationship be-
tween DGM atrophy and cognitive domains in
a large homogenous cohort of patients with
early relapsing-remitting MS (RRMS).
METHODS Participants. A total of 170 subjects were in-
cluded, of which 50 were healthy controls (30 women) and 120
had RRMS21 (80 women). All patients were part of the 6-year
follow-up of an early inception cohort, in which patients were
included at (or closely before) diagnosis and subsequently fol-
lowed annually. All groups were comparable with respect to age
and education level. Physical disability was measured using the
Expanded Disability Status Scale (EDSS)22 and was relatively
mild (median EDSS 2.0, range 0.0–6.0). Patients were relapse-
free and without steroid treatment for at least 2 months. Con-
trols were recruited from the Amsterdam area using existing
databases.
Sixty-nine patients (56.5% of all patients, 42 female) had
taken disease-modifying therapies (DMT) in the past or at pres-
ent. Treatment dose, onset, duration, and sequence varied be-
tween patients, but treatment duration of those patients who
received DMT was equal between the sexes (women: 62.9 
27.3 months and men: 61.2  30.0 months, Z  0.50, p 
0.61). Forty-eight patients (30 women) used some form of
DMT during the study period, namely -interferon (30 pa-
tients, 20 women), natalizumab (10 patients, 5 women), glati-
ramer acetate (7 patients, 4 women), and immunosuppressive
therapy (1 female patient).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional ethics
review board and all subjects gave written informed consent
prior to participation.
MRI. Subjects received structural 3T MRI scans (GE Signa-
HDXT), using 3D-T1 gradient-echo, 2D dual-echo T2, and 2D
spin-echo T1 sequences (see e-Methods on the Neurology® Web
site at www.neurology.org for more details). Subjects for whom
MRI data were unavailable (4 of the 120 patients) were only
included in cognitive evaluations.
Neuropsychological evaluation. Subjects underwent a
comprehensive set of neuropsychological tests comprised of the
Brief Repeatable Battery for Neurological disease (BRB-N),15 as
well as the concept shifting test, the Stroop color-word test, and
the memory comparison test. This resulted in an evaluation of 7
cognitive domains: executive functioning, verbal memory, infor-
mation processing speed, visuospatial memory, working mem-
ory, attention, and psychomotor speed (see e-Methods). An
“average cognition” Z score was calculated by averaging Z scores
of all separate domains.
Patients who scored at least 1.5 SDs (i.e., Z 1.5) below the
average of controls in 2 or more domains were defined as “cogni-
tively impaired.”
Brain and lesion volumes. T2-hyperintense and T1-
hypointense lesions were marked by an experienced rater and
volumes were measured using a local thresholding technique.
Brain volumes were analyzed on the 3D-T1 sequence. Excess
neck tissue was removed by a registration of a Montreal Neuro-
logical Institute standard brain image to each individual scan to
identify the lower border of the brain. Normalized total GM
(NGMV), total WM (NWMV), and whole brain volume
(NBV), corrected for head size, were measured using SIENAX23
version 2.5 (part of FSL4.1, http://www.fmrib.ox.ac.uk/fsl).
SIENAX was run using standardized parameters for brain extrac-
tion, including automatic estimation of the center of the head.
DGM volumes were measured using FIRST19 (also part of FSL),
providing left and right volumes for the thalamus, caudate, glo-
bus pallidus, putamen, hippocampus, amygdala, and nucleus ac-
cumbens in a 2-step process (see e-Methods). Afterwards,
normalized DGM volumes were pooled to form a total normal-
ized deep GM volume (NDGMV). In addition, to allow explo-
ration of the separate effect of cortical atrophy on cognition, we
estimated normalized cortical GM volume (NCGMV) by re-
moving individual FIRST regions of interest from the SIENAX-
based NGMV images (figure e-1). Both NDGMV and
NCGMV were included in the statistical analyses (details given
below). We excluded from those analyses total NGMV and
NWMV, because of known SIENAX segmentation problems in
regions of deep GM, and WM lesion misclassification.
Statistical analysis. Variables were checked for normality us-
ing Kolmogorov-Smirnov and histogram inspection. T1 and T2
lesion volumes were log-transformed. All analyses used age and
education level as covariates (where applicable) and were
Bonferroni-corrected for multiple comparisons.
General linear models. Cognitive and volumetric variables
were separately analyzed using multivariate general linear model
(GLM) analyses, using group as a fixed factor, with 4 levels:
female patient, male patient, female control, male control. Post
hoc Bonferroni analyses included 4 comparisons, namely male
patients vs male controls, female patients vs female controls,
male controls vs female controls, and male patients vs female
patients. Sex was investigated as such to further subdivide the
large homogeneous group of patients to further explore possible
effects. To investigate effect sizes of atrophic changes, Cohen d
(dividing the mean difference by a pooled SD) and percentage
volume change were calculated.
Relation of atrophy with cognition. NGMV, NDGMV,
NCGMV, and lesion volumes were correlated with average cog-
nition using Pearson correlation coefficient. To investigate inde-
pendent contributions of individual DGM structures, stepwise
linear regression was used to predict average cognition Z scores
of all 107 patients (71 women) who received both MRI and
cognitive evaluations. Control data were not included in the re-
gression model. To limit the number of variables, only signifi-
cantly atrophic DGM structures were used as predictors in the
regression model. These were entered in the analysis together
with sex, EDSS (dichotomized by a median split), disease dura-
tion (since first symptom), T1 and T2 lesion volumes, age, and
education (also dichotomized). As there is a large overlap be-
tween GM volumes calculated by SIENAX and by FIRST, with
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the latter being much more sensitive to DGM volume changes,
only individual FIRST-based volumes were entered in the regres-
sion models.
RESULTS Subjects. There were no differences be-
tween male and female patients regarding EDSS, T1
or T2 lesion volumes, or disease duration (table 1).
Cognition. Multivariate GLM analyses showed a
main effect of group for all cognitive domains except
visuospatial memory, which was further excluded
(table 2). Post hoc Bonferroni pairwise comparisons
revealed all remaining cognitive Z scores to be signif-
icantly lower in male patients compared to male con-
trols and all except working memory compared to
female patients. Female patients did not score signif-
icantly lower than female controls in any cognitive
domain. The 2 cognitive domains that showed the
lowest Z score in the entire patient group were work-
ing memory (Z  0.78) and information process-
ing speed (Z  0.60). Thirty-four patients (28%)
were classified as cognitively impaired, specifically 20
female patients (25%, average cognition Z  1.0)
vs 14 male patients (35%, average cognition Z 
1.7). Male and female controls did not differ sig-
nificantly from each other in any of the cognitive
domains. Average cognition correlated with EDSS
(rho  0.37, p  0.001).
Brain volume. Multivariate GLM analyses showed a
main effect of group for all brain volumes except for
the amygdalae bilaterally, which were further ex-
cluded (table 2). Post hoc comparisons revealed a re-
duction in NWMV for both sexes, while NGMV
and NBV were only reduced in men (table e-1). All
DGM volumes were reduced in male patients com-
pared to male controls except for the hippocampus
bilaterally and the right nucleus accumbens (table
e-1, NDGMV reduction of 7.2 mL [11.0% volume
loss], Cohen d  1.25). In female patients, all
DGM volumes were reduced compared to female
controls except for the putamen bilaterally, as well as
right hippocampus and right nucleus accumbens (ta-
ble e-1, NDGMV reduction of 4.1 mL [6.3% vol-
ume loss], Cohen d  0.85). Male patients,
compared to female patients, showed significantly
smaller volumes in the left and right caudate nucleus,
as well as the right putamen (table e-1). All signifi-
cant volume reductions were more pronounced in
male patients. See figure 1 for an example of matched
male and female patients.
DGM atrophy was strongest in the left caudate
nucleus for male patients (16%), and the left palli-
dum for female patients (9%). Very strong reduc-
tions in NDGMV, defined as at least 2 standard
deviations below sex-matched controls, were found
in 23 patients (20%), specifically 13 women (16%,
of which 4 were cognitively impaired) vs 10 men
(28%, of which 5 were cognitively impaired). In the
control group, no volumes significantly differed be-
tween the sexes.
Relating atrophy and lesion volumes to cognition. In
the patient group, significant correlations were found
between average cognition and NGMV (r 0.21, p
0.03), NCGMV (r 0.29, p 0.002), and NDGMV
(r 0.38, p 0.0001). Significance in all correlations
was driven by male patients (r  0.34, p  0.04 for
NGMV; r  0.37, p  0.03 for NCGMV; r  0.60,
p 0.0001 for NDGMV) as no correlation with aver-
age cognition was significant for female patients. In the
entire patient group, only T2 lesion volumes correlated
with NGMV (r0.22, p 0.02). T1 and T2 lesion
volumes correlated withNDGMV (r0.37 and r
0.43, respectively, p 0.0001 for both) but not with
NCGMV. Interestingly, this correlation was stronger in
male patients (T1: r  0.45, p  0.007; T2: r 
0.51, p  0.002) than in female patients (T1: r 
0.33, p 0.004; T2: r0.36, p 0.001), while
lesion volumes were equal between both sexes (T1:
Mann-Whitney Z  0.90, p  0.37; T2: Z 
1.31, p  0.19). A direct correlation between lesion
Table 1 Descriptive variables for controls and patients andMann-Whitney Z and p values, comparing male
and female patient groups
Female controls
(n 30),
mean SD
Male controls
(n 20),
mean SD
Female patients
(n 80), mean SD
or median (range)
Male patients
(n 40), mean SD
or median (range) Z p
Age, y 40.9 11.0 39.6 11.6 39.6 8.3 40.4 9.0 0.52 0.61
Education (range 1–7) 5.5 1.5 5.7 1.6 4.9 1.5 5.0 1.5 0.14 0.89
EDSS (range 1–10) 2.0 (0–6) 2.0 (0–5) 0.77 0.44
Disease duration, y 7.5 2.3 7.6 1.9 1.02 0.31
T1 lesion volume, mL 1.7 2.5 2.1 2.5 0.83 0.41
T2 lesion volume, mL 3.5 3.9 4.7 4.9 1.18 0.24
T1/T2 volume ratio 0.43 0.20 0.41 0.20 0.52 0.61
Abbreviation: EDSS Expanded Disability Status Scale.
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volumes and average cognition was only found for T1
lesion volumes in male patients (r0.33, p 0.05).
Linear regression of cognition. Right thalamic vol-
ume, sex, and education were the only significant
predictors of average cognition, indicating poorer
cognitive performance to be related with lower tha-
lamic volumes and male sex, together with lower ed-
ucation. Right thalamic volume correlated directly
with average cognition in the entire patient group
(r  0.37, p  0.0001), as did left thalamic volume
(r  0.34, p  0.0002). Both correlations were
driven by male patients (r  0.60, p  0.0001 and
r  0.57, p  0.0003, respectively); none were sig-
nificant in women (figure 2).
Across cognitive domains, performance was to
some extent predicted by DGM atrophy. Psychomo-
tor speed and verbal memory were best explained by
the regression model. Sex was a significant predictor
in all domains except information processing speed
and working memory. The most prevalent structure
was the thalamus, which was a predictor of all do-
mains except verbal and working memory, where the
caudate appeared to be more important. See table 3
for more details and statistics.
Table 2 Cognitive and volumetric variables for controls and patientsa
Controls, mean SD Patients, mean SD GLMmain effect
Female (n 30) Male (n 20) Female (n 80) Male (n 40) F p
Cognitive Z scores
Executive functioning 0.02 0.68 0.02 0.62 0.29 0.86 0.83 1.32 5.72 0.0010
Verbal memory 0.03 0.94 0.06 0.89 0.16 0.91 1.03 0.92 10.14 0.0001
Processing speed 0.03 1.09 0.04 0.86 0.39 1.08 0.99 1.16 5.48 0.0013
Visuospatial memory 0.15 1.15 0.24 0.67 0.51 1.24 0.15 0.94 2.16 0.0955
Workingmemory 0.06 0.86 0.09 0.92 0.63 1.40 1.09 1.25 4.08 0.0081
Attention 0.01 0.65 0.02 0.56 0.31 0.69 0.89 1.09 7.64 0.0001
Psychomotor speed 0.00 0.87 0.00 0.65 0.38 0.94 0.97 1.23 6.57 0.0003
Average cognition 0.03 0.63 0.05 0.46 0.39 0.67 0.85 0.85 9.39 0.0001
Whole brain volumes, mL
NGMV 839.87 44.47 842.36 57.88 828.60 42.92 808.62 47.85 4.40 0.0053
NWMV 679.52 29.03 701.91 36.02 660.80 33.68 665.54 36.06 9.80 0.0001
NBV 1,519.40 62.59 1,544.27 84.83 1,489.41 64.04 1,474.16 66.53 7.60 0.0001
NCGMV 791.48 51.86 792.01 61.98 777.14 48.67 740.51 52.77 8.98 0.0001
NDGMV 65.15 3.92 64.81 3.90 61.02 5.20 57.65 6.68 14.96 0.0001
Deep GM volumes, mL
Thalamus L 10.70 0.71 10.69 0.82 9.92 0.94 9.41 1.26 14.00 0.0001
Thalamus R 10.39 0.71 10.52 0.63 9.73 0.85 9.36 1.40 10.21 0.0001
Caudate L 4.87 0.47 4.95 0.36 4.55 0.61 4.17 0.65 12.00 0.0001
Caudate R 5.07 0.46 5.05 0.56 4.76 0.62 4.37 0.57 10.48 0.0001
Putamen L 6.60 0.81 6.74 0.75 6.28 0.68 6.01 0.97 6.01 0.0007
Putamen R 6.68 0.78 6.62 0.58 6.41 0.68 6.02 0.72 6.56 0.0003
Pallidum L 2.40 0.26 2.40 0.15 2.22 0.24 2.08 0.38 11.67 0.0001
Pallidum R 2.45 0.21 2.44 0.18 2.28 0.26 2.17 0.28 9.81 0.0001
Hippocampus L 5.37 0.58 5.13 0.62 4.97 0.66 4.67 0.66 6.46 0.0004
Hippocampus R 5.48 0.50 5.22 0.57 5.14 0.62 4.82 0.68 6.25 0.0005
Amygdala L 1.82 0.27 1.83 0.28 1.70 0.31 1.68 0.33 2.21 0.0886
Amygdala R 1.91 0.31 1.84 0.38 1.80 0.27 1.73 0.32 1.69 0.1704
Nucleus accumbens L 0.80 0.12 0.79 0.10 0.70 0.13 0.64 0.13 9.72 0.0001
Nucleus accumbens R 0.62 0.14 0.60 0.09 0.56 0.11 0.52 0.17 3.69 0.0132
Abbreviations: GLM  general linear model; GM  gray matter; NBV  normalized whole brain volume; NCGMV  normal-
ized cortical gray matter volume; NDGMV  normalized deep gray matter volume; NGMV  normalized total gray matter
volume; NWMV normalized total white matter volume.
a All volumes have been corrected for head size. See table e-1 for post hoc GLM p values comparing patients to controls.
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DISCUSSION In this study, we investigated the re-
lationship between DGM atrophy and cognition in
MS using a well-characterized inception cohort, 6
years after diagnosis. In this cohort of patients with
RRMS with relatively mild disability and low lesion
volumes (table 1), DGM structures show extensive
atrophy, and the degree of atrophy correlates strongly
with cognitive dysfunction. Cognitive impairment
was found in 28% of all patients with MS. Cognitive
dysfunction was most prominent in the domains of
working memory and information processing speed,
which confirms previous results.12 Although visu-
ospatial memory was previously found to be im-
paired in MS,12 patients in this study did not score
abnormally on SPART, the visuospatial memory test
of the BRB-N battery administered to all partici-
pants, possibly due to the relatively low sensitivity of
SPART.24 Cognitive abnormalities were more severe
in male patients. Strikingly, none of the domains
were abnormal in the female patient group. Male pa-
tients were more frequently cognitively impaired,
and their impairment was also more severe, which is
Figure 1 Three-dimensional T1 scans and FIRST volumes for a matchedmale and female patient
(A) Male patient, 47 years old, education level 6, average cognition Z  3.1, deep gray matter volume 44% below male controls. (B) Female patient, 45
years old, education level 5, average cognition Z0.1, deep gray matter volume 5% below female controls.
Figure 2 Cognitive correlations of thalamic volume
The relationship between right thalamus volume and average cognition in female (MS F) and male (MS M) patients. MS 
multiple sclerosis.
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in line with previous studies showing male sex to be a
significant predictor of cognitive impairment in
larger groups of patients.13,20
DGM atrophy was most pronounced in the cau-
date, pallidum, and thalamus, although all DGM
structures were found to be atrophic, except bilateral
amygdala and the right hippocampus and nucleus
accumbens. Volume reductions were generally larger
in male patients (table e-1). This sex effect on atro-
phy has not been shown in such detail before. Studies
that have investigated sex effects on brain volumes
have mainly been restricted to overall atrophy
measures like NGMV.25 Here, we show that DGM
atrophy exhibits larger effect sizes than NGMV
(table e-1).
The relationship between brain volume and cog-
nition was stronger for subcortical GM volume than
it was for cortical GM volume. Zooming in on sub-
cortical structures, specific MRI predictors of cogni-
tion varied per cognitive domain. The most
commonly affected structure was the thalamus,
which was the sole MRI predictor of average cogni-
tive performance. It was also a significant predictor
of executive functioning, information processing
speed, attention, and psychomotor speed domains.
The predictive value of the thalamus for cognition is
in line with earlier research.26 Using similar methods,
a recent study showed the importance of the thala-
mus for information processing speed,19 which is
confirmed by our results. Additionally, this study
also found the putamen to be important for this do-
main. In our regression analysis, the putamen was
not significant as a predictor, but did correlate with
information processing speed in male patients only
(r  0.49, p  0.002). Sex-specific relations were
seen in most cognitive domains involving the thala-
mus except for information processing speed, where
sex was not a significant predictor. Atrophy of the
thalamus was present in both male and female pa-
tients, but only correlated with average cognition in
male patients. Female patients did have thalamic at-
rophy, but showed little cognitive dysfunction. This
might be explained by a relative lack of atrophy in
other DGM structures in female patients compared
to male patients (table e-1).
The 2 memory-based domains, verbal memory
and working memory, were influenced by caudate
atrophy, with verbal memory also being influenced
by hippocampal volume and sex. A previous fMRI
study has highlighted the importance of the caudate
nucleus for cognition, although only in primary pro-
gressive MS,27 showing hyperactivation in cogni-
tively preserved compared to cognitively impaired
patients. This process of hyperactivation of normally in-
volved regions of the brain and/or recruiting additional
regions is often termed functional reorganization.27 A
recent study has also shown the hippocampus to be in-
volved in functional reorganization in MS.28
Lesion volumes did not display a direct correla-
tion with average cognitive performance, apart from
T1 lesion volumes in male patients. In the regression
models, T2 lesion volumes partly predicted executive
function. Although the direct relationship between
lesion volumes and cognition appeared to be weak,
there was a significant correlation between lesion vol-
umes and DGM atrophy. Although lesion volumes
were equal between male and female patients, their
relationship with atrophy was stronger in men. This
Table 3 Linear stepwise regression of cognition
Model Predictor
Adjusted R2 F p Standardized  t p
Executive function 0.29 9.91 0.0001
Thalamus R 0.53 5.24 0.0001
Education 0.30 3.76 0.0003
T2 volume 0.24 2.72 0.0077
Sex 0.19 2.26 0.0256
Nucleus
accumbens L
0.19 2.00 0.0485
Verbal memory 0.31 11.06 0.0001
Sex 0.30 3.70 0.0003
Education 0.23 2.93 0.0041
Hippocampus L 0.21 2.43 0.0169
Disease duration 0.19 2.36 0.0202
Caudate L 0.17 1.97 0.0511
Processing speed 0.27 21.85 0.0001
Education 0.38 4.72 0.0001
Thalamus R 0.38 4.66 0.0001
Workingmemory 0.15 7.60 0.0001
Caudate L 0.37 3.70 0.0003
Nucleus
accumbens L
0.29 2.98 0.0036
Education 0.21 2.39 0.0187
Attention 0.22 8.26 0.0001
Education 0.31 3.58 0.0005
Sex 0.29 3.29 0.0014
Thalamus R 0.29 2.91 0.0045
Hippocampus L 0.24 2.38 0.0189
Psychomotor speed 0.31 17.79 0.0001
Education 0.37 4.72 0.0001
Thalamus R 0.37 4.69 0.0001
Sex 0.17 2.17 0.0322
Average cognition 0.31 18.04 0.0001
Education 0.39 4.96 0.0001
Thalamus R 0.34 4.33 0.0001
Sex 0.20 2.52 0.0133
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could possibly indicate that the male brain is more
sensitive to neurodegeneration secondary to lesional
damage in MS, although this is speculation. In our
analyses, we did not consider the anatomic locations
of lesions; this may be another factor influencing the
effect of lesions on clinical and cognitive function-
ing, as previously shown.29
Sex seems to be an important factor that influ-
ences MS evolution. For example, in the chronic
phase of MS, GM atrophy becomes more dominant4
and male patients reach this stage of the disease ear-
lier.30 Although male patients appear to have more
atrophy in general,25 studies using larger sample sizes
and appropriate controls are lacking.31 Notably, sev-
eral studies found no differences between male and
female patients, but did not directly address sex-
specific disease-inflicted atrophy by comparing to
sex-matched healthy controls.31 Neuroanatomic sex
differences are widespread in healthy controls, how-
ever. For example, men have larger overall brain vol-
umes as well as larger relative WM volumes, while
women have larger relative GM volumes.32 Recent
studies on network properties also indicate a larger
efficiency in female structural networks,33,34 as well as
differences in how functional network properties re-
late to cognition.35 Interestingly, the thalamus exhib-
its extensive sex effects in WM fractional anisotropy,
along with many other regions of the brain.36 There-
fore, in our large study, we compared both male and
female patients directly with sex-matched controls.
This showed that both DGM atrophy and cognitive
dysfunction were worse in males, although it is insuffi-
ciently clear why. Possibly estrogen may serve as a pro-
tective factor inMS, as suggested by animal models,37–39
but this awaits confirmation in human studies.
Although the present study displays clear effects
and relationships, the results are based on cross-
sectional data, focused on DGM volume. Future
studies will have to investigate cortical atrophy in
more detail, as the methodology used in this study
was mainly limited to DGM structures. The strength
of this study is the large cohort of patients with
closely matched disease duration. Nevertheless, our
findings should be confirmed in other MS cohorts.
Future studies should also investigate the progression
of atrophy within individual patients and possible
changes in the relationship between atrophy and cog-
nitive dysfunction along the disease course. This is
especially relevant when designing new treatment
strategies, which could thus differ between male and
female patients.
These results show a clear relationship between
cognitive dysfunction and subcortical atrophy in MS
in a cohort of patients with RRMS 6 years postdiagno-
sis. This relationship was mostly driven by the thala-
mus, which was strongly predictive of most cognitive
domains. Male sex was also found to be an important
predictor of a worse cognitive performance and of
higher regional atrophy. Future studies will have to shed
more light onto the causes of these distinct sex differ-
ences, and will as such hopefully effectuate a more
evolved understanding of neurodegenerative processes
and cognitive impairment in MS.
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